NSCLC Resource Center Quiz #3

Approximately how many lung adenocarcinomas have KRAS mutations?
50%
30%
13%
22%
KRAS mutations are associated more with smoking than non-smoking.
True
False
Which of the following agents are currently approved to treat patients with advanced NSCLC?
Gefitinib
Savolitinib
Osimertinib
Sotorasib
The mechanism of action for sotorasib involves which of the following?
Downstream effectors of activated KRAS
Blockade of upstream signaling pathways
Direct inhibition of KRAS
Targeting RAS activation
0
{"name":"NSCLC Resource Center Quiz #3", "url":"https://www.poll-maker.com/QT3N6AJ5H","txt":"Approximately how many lung adenocarcinomas have KRAS mutations?, KRAS mutations are associated more with smoking than non-smoking., Which of the following agents are currently approved to treat patients with advanced NSCLC?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}